Evidence map›Paper›PMID 39394843›Full record

ArticleCancer medicine2024

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies.

Benjamin J Lee, Jenny Liu, Shawn P Griffin, Jean Doh, Stefan O Ciurea, Piyanuch Kongtim, Elizabeth A Brem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Benjamin J LeeDepartment of Pharmacy, University of California Irvine Health, Orange, California, USA.ORCID https://orcid.org/0000-0002-1678-1345
Jenny LiuDepartment of Pharmacy, University of California Irvine Health, Orange, California, USA.
Shawn P GriffinDepartment of Pharmacy, University of California Irvine Health, Orange, California, USA.ORCID https://orcid.org/0000-0002-3818-2490
Jean DohDepartment of Pharmacy, University of California Irvine Health, Orange, California, USA.ORCID https://orcid.org/0000-0003-2737-5243
Stefan O CiureaDepartment of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.ORCID https://orcid.org/0000-0001-8597-3271
Piyanuch KongtimDepartment of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.ORCID https://orcid.org/0000-0003-2130-7645
Elizabeth A BremDepartment of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.ORCID https://orcid.org/0000-0002-3265-9841

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

introductionBlastoid variant-mantle cell lymphoma (BV-MCL) represents an aggressive subset of patients with no established standard of care treatment approach.

methodsWe performed a retrospective analysis of the clinical characteristics and outcomes of 17 de novo BV-MCL patients treated at our institution between May 2009 and September 2023. In addition, we reviewed the literature supporting 2nd/3rd generation Bruton's Tyrosine-kinase (BTKi)-based therapies for upfront management.

resultsThe complete response rate to frontline and salvage therapy was 66.7% and 25%, respectively. Two-year overall survival (OS) was low at 62.5% (95% CI, 34.7%-81.1%). Variables associated with higher OS included receipt of consolidative HSCT (p = 0.017), TP53-wild type (p = 0.031), intermediate- versus high-risk Mantle Cell Lymphoma Prognostic Index score (p = 0.026), and achieving complete response with induction therapy (p = 0.027). DISCUSSION: Treatment outcomes with chemo-immunotherapy in BV-MCL patients are poor, especially among TP53-mutated patients. Recent findings describing positive outcomes with novel BTKi-based therapies are encouraging and should be considered in this high-risk population.

Indexed as

Agammaglobulinaemia Tyrosine KinaseLymphoma, Mantle-CellProtein Kinase InhibitorsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedRetrospective StudiesSalvage TherapyTreatment OutcomeTumor Suppressor Protein p53Agammaglobulinaemia Tyrosine KinaseBTK protein, humanProtein Kinase InhibitorsTumor Suppressor Protein p53Tyrosine Kinase Inhibitorsblastoid variantBruton tyrosine kinase inhibitormantle cell lymphoma

Identifiers

PMID39394843
PMCPMC11470199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.